Global Impetigo Therapeutic Market is Segmented By Treatment Type (Antibiotic Ointments, Antibiotic Tablets), By Route of Administration (Oral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
Global Impetigo Therapeutic Market reached US$ 532.0 million in 2023 and is expected to reach US$ 931.86 million by 2031, growing at a CAGR of 7.4% during the forecast period 2024-2031.
Impetigo is a common infection of the superficial layers of the epidermis that is highly contagious and most commonly caused by gram-positive bacteria. It most commonly presents as erythematous plaques with a yellow crust and may be itchy or painful. The lesions are highly contagious and spread easily.
Impetigo occurs when the skin becomes infected with bacteria, usually either Staphylococcus aureus or Streptococcus pyogenes. These bacteria can infect the skin in 2 ways, through a break in healthy skin, such as a cut, insect bite, or other injury, which is known as primary impetigo.
Market Summary
Metrics | Details |
CAGR | 7.4% |
Market Size Available for Years | 2022-2031 |
Estimation Forecast Period | 2024-2031 |
Revenue Units | Value (US$ Mn) |
Segments Covered | Treatment Type, Route of Administration, Distribution Channel |
Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
Largest Region | North America |
Fastest Growing Region | Asia-Pacific |
Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Rising adoption of antibiotics
The rising adoption of antibiotics is expected to drive the market growth. Antibiotics, particularly topical options such as mupirocin, are effective against the bacteria that frequently cause impetigo. Their effectiveness encourages healthcare providers to prescribe them more frequently, which boosts market sales.
The innovation of new antibiotic formulations, especially combination medicines that improve efficacy and prevent resistance, can help boost market growth by giving healthcare practitioners more treatment alternatives. Impetigo is most common in children, therefore the growing pediatric population can result in more antibiotic prescriptions for this condition.
Limited awareness
Limited awareness among individuals about the disease condition and the available treatment options is expected to hinder market growth. This can affect the market growth as very few individuals access the treatment options. This can discourage the market players from continuing therapeutic manufacturing.
Market Segment Analysis
The global impetigo therapeutic market is segmented based on treatment type, route of administration, distribution channel and region.
Antibiotic ointments segment is expected to dominate the market share
The antibiotic ointments segment is expected to hold a significant portion of the market share. Ointments are intended for direct application to the skin, allowing for localized treatment that accurately targets the infection at its point of origin. This increases effectiveness while limiting exposure to the rest of the body. Antibiotic ointments can give quicker symptom relief and encourage faster healing of skin lesions, making them a popular choice among patients looking for quick results.
Compared to oral antibiotics, ointments have a lower risk of systemic side effects. This safety profile is especially significant for pediatric patients and those with existing medical conditions. These features are expected to increase the demand for antibiotic ointments during the forecast period.
Market Geographical Share
North America is expected to hold a significant position in the impetigo therapeutic market share
North America is expected to hold a significant position in the global impetigo therapeutics market during the forecast period due to the rising prevalence of impetigo in the region. The presence of a large number of pharmaceutical companies in the region is expected to hold the region in the dominant position.
Pharmaceutical companies in North America manufacture a wide variety of antibiotic creams and tablets that treat impetigo conditions. The increase in the infections in the region leads the individuals to use antibiotic ointments and tablets which could increase the market expansion. Thus, the above factors are expected to hold the region in a significant position during the forecast period.
Market Segmentation
By Treatment
- Antibiotic Ointments
- Mupirocin (Bactroban & Centany)
- Retapamulin
- Ozenoxacin
- Fusidic Acid
- Others
- Antibiotic Tablets
- Cephalosporins
- Clindamycin (Cleocin)
- Amoxicillin-Clavulanate
- Sulfamethoxazole (Bactrim)
- Others
By Route of Administration
- Oral
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Market Competitive Landscape
The major global players in the market include Medimetriks Pharmaceuticals, Inc., Biofrontera Inc., GSK plc, Pfizer Inc., AdvaCare Pharma, Wellona Pharma, Glenmark Pharmaceuticals Inc., USA, Teva Pharmaceuticals USA, Inc., Stelon Biotech and DM Pharma among others.
Key Developments
- In March 2024, a new vaccine trial for mpox (formerly known as Impetigo Therapeutic) is being launched in the UK to secure public health, the National Institute for Health and Care Research (NIHR) has announced. Delivered by the NIHR Clinical Research Network, the mPower clinical trial will investigate the efficacy of an mRNA mpox vaccine.
- On August 27, 2024, Siemens Healthineers received the Central Drugs Standard Control Organisation's (CDSCO) approval to manufacture the Impetigo Therapeutic detection RT-PCR kit.
Why Purchase the Report?
- To visualize the global impetigo therapeutic market segmentation based on treatment type, route of administration, distribution channel, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of impetigo therapeutic market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global impetigo therapeutic market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
